From October 1, 2023 to December 20, 2023, the company has repurchased 244,200 shares, representing 0.23% for CNY 15.94 million. With this, the company has completed the repurchase of 777,300 shares, representing 0.72% for CNY 49.99 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
71.85 CNY | -1.83% | +4.34% | +10.37% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.37% | 1.08B | |
+24.98% | 46.71B | |
+48.83% | 41.8B | |
-1.18% | 41.52B | |
-3.42% | 29.55B | |
+10.48% | 25.78B | |
-21.06% | 19.26B | |
+1.58% | 12.14B | |
-3.41% | 12.08B | |
+27.24% | 11.98B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.